{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:18:19Z","timestamp":1786976299699,"version":"build-2736575974"},"reference-count":41,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,1,28]],"date-time":"2014-01-28T00:00:00Z","timestamp":1390867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Care &amp;amp; Research"],"published-print":{"date-parts":[[2014,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Diffuse alveolar hemorrhage (DAH) is an uncommon complication of primary antiphospholipid syndrome (APS). We aimed to describe the clinical characteristics, treatment, and outcomes of primary APS\u2013associated DAH in a single center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective review of all adults with primary APS\u2013associated DAH evaluated at Mayo Clinic over a 15\u2010year period. DAH was defined as bilateral pulmonary infiltrates and bronchoalveolar lavage (BAL) fluid documenting progressively bloody returns and\/or the presence of &gt;20% hemosiderin\u2010laden macrophages. Patients with other causes of DAH were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighteen patients were identified (median age 43 years). Capillaritis was present in surgical lung biopsy samples of 3 patients. BAL differential cell counts revealed predominantly neutrophils. All patients were treated initially with glucocorticoids. Cyclophosphamide (CYC) was used in 8 patients; complete remission was achieved in 3 patients treated with CYC alone and in 1 patient receiving combination therapy with rituximab (RTX). RTX was used in 9 patients; 2 patients achieved remission with RTX alone, whereas 3 patients required combination therapy with CYC or mycophenolate mofetil (MMF). No patient achieved complete remission while receiving single therapy with MMF, azathioprine, or plasma exchange. Intravenous gamma globulin therapy was administered in 5 patients; no patient achieved control of the disease. Six patients died, all because of complications related to uncontrolled DAH or its therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We present the largest case series of primary APS\u2013associated DAH reported in the literature. DAH carries a very poor prognosis and therapeutic options are limited. Immunosuppression with either CYC or RTX is associated with the highest likelihood of remission induction and should be considered early.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/acr.22109","type":"journal-article","created":{"date-parts":[[2013,8,27]],"date-time":"2013-08-27T16:40:47Z","timestamp":1377621647000},"page":"301-310","source":"Crossref","is-referenced-by-count":56,"title":["Primary Antiphospholipid Syndrome\u2013Associated Diffuse Alveolar Hemorrhage"],"prefix":"10.1002","volume":"66","author":[{"given":"Rodrigo","family":"Cartin\u2010Ceba","sequence":"first","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Peikert","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneel","family":"Ashrani","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Keogh","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Wylam","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Ytterberg","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Specks","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,28]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2012.08.001"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.08-2084"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-836146"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200101000-00003"},{"key":"e_1_2_6_6_1","first-page":"777","article-title":"Massive pulmonary hemorrhage in a Saudi female with primary antiphospholipid syndrome","volume":"21","author":"Al\u2010Hajjaj MS","year":"2000","journal-title":"Saudi Med J"},{"key":"e_1_2_6_7_1","first-page":"554","article-title":"Pulmonary capillaritis and alveolar hemorrhage associated with the antiphospholipid antibody syndrome","volume":"22","author":"Crausman RS","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.05.006"},{"key":"e_1_2_6_9_1","first-page":"805","article-title":"Diffuse alveolar hemorrhage in the antiphospholipid syndrome: spectrum of disease and treatment","volume":"26","author":"Gertner E","year":"1999","journal-title":"J Rheumatol"},{"key":"e_1_2_6_10_1","first-page":"1224","article-title":"Pulmonary capillaritis, alveolar hemorrhage, and recurrent microvascular thrombosis in primary antiphospholipid syndrome","volume":"20","author":"Gertner E","year":"1993","journal-title":"J Rheumatol"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/03009749109165923"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2008.06.006"},{"key":"e_1_2_6_13_1","first-page":"125","article-title":"Pulmonary haemorrhage and primary antiphospholipid syndrome: case report and review","volume":"24","author":"Marcos Rodriguez PJ","year":"2007","journal-title":"An Med Interna"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2565(04)71534-9"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203311422713"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.51.6592"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1843.1999.00212.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"e_1_2_6_20_1","first-page":"567","article-title":"Recurrent deep vein thrombosis, thromboembolic pulmonary hypertension and the \u2018primary\u2019 antiphospholipid syndrome","volume":"7","author":"Jeffrey PJ","year":"1989","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.43.5.760"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350616"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-200009000-00012"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu394oa"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.3.195"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2010.05.005"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00124743-200102000-00007"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200318817"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.037671"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2001.26345"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1159\/000236883"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1997.tb00200.x"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.9.900"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400322"},{"key":"e_1_2_6_35_1","first-page":"397","article-title":"Vasculitis in the antiphospholipid syndrome: culprit or consort?","volume":"21","author":"Lie JT","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_6_36_1","first-page":"1694","article-title":"A longitudinal study of anticardiolipin antibody in polymyalgia rheumatica and giant cell arteritis","volume":"22","author":"Chakravarty K","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199804)41:4<701::AID-ART18>3.0.CO;2-P"},{"key":"e_1_2_6_38_1","first-page":"474","article-title":"Anticardiolipin antibodies in polymyalgia rheumatica\u2010giant cell arteritis: association with severe vascular complications","volume":"90","author":"Espinoza LR","year":"1991","journal-title":"Am J Med"},{"key":"e_1_2_6_39_1","first-page":"1478","article-title":"Lipoprotein(a) and anticardiolipin antibodies as risk factors for thrombotic events in polymyalgia rheumatica and giant cell arteritis","volume":"23","author":"Seriolo B","year":"1996","journal-title":"J Rheumatol"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704432"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0330"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.148"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Facr.22109","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.22109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T15:22:43Z","timestamp":1759418563000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.22109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,28]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["10.1002\/acr.22109"],"URL":"https:\/\/doi.org\/10.1002\/acr.22109","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,28]]}}}